Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™

Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs

Vasconcelos, T., Sarmento, B. F. C. C., & Costa, P. C. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.09.005 · Cited by 1,573 · see citing works

Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates

Blagden, N., de Matas, M., Gavan, P. T., & York, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.011 · Cited by 1,452 · see citing works

THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870 · see citing works

Characterization of Interintestinal and Intraintestinal Variations in Human CYP3A-Dependent Metabolism

Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 790 · see citing works

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662 · see citing works

Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Bioavailability

Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00179-x · Cited by 651 · see citing works

Cytochrome P450s and other enzymes in drug metabolism and toxicity

Guengerich, F. P. (2006) · The AAPS Journal · doi:10.1208/aapsj080112 · Cited by 623 · see citing works

Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4

Bhardwaj, R., Glaeser, H., Becquemont, L., Klotz, U. E., Gupta, S. K., & Fromm, M. F. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034728 · Cited by 555 · see citing works

Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

Zhao, P., Zhang, L., Grillo, J. A., Liu, Q., Bullock, J. M., Moon, Y. J., Song, P., Brar, S. S., Madabushi, R., Wu, T. C., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.298 · Cited by 524 · see citing works

Correlation of Human Jejunal Permeability (in Vivo) of Drugs with Experimentally and Theoretically Derived Parameters. A Multivariate Data Analysis Approach

Winiwarter, S., Bonham, N. M., Ax, F., Hallberg, A., Lennernäs, H., & Karlén, A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810102 · Cited by 458 · see citing works

A compartmental absorption and transit model for estimating oral drug absorption

Yu, L. X., & Amidon, G. L. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00147-7 · Cited by 455 · see citing works

Population-Based Mechanistic Prediction of Oral Drug Absorption

Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., & Tucker, G. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9099-y · Cited by 452 · see citing works

Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial

STOLTZ, M., REYNOLDS, D., ELKINS, L., SALAZAR, D., & Weir, S. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90252-x · Cited by 440 · see citing works

First-pass metabolism of cyclosporin by the gut

Kolars, J. C., Watkins, P. B., Merion, R. M., & Awni, W. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)92302-i · Cited by 423 · see citing works

Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes

Rodgers, T., & Rowland, M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9210-3 · Cited by 420 · see citing works

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates

Jamei, M., Dickinson, G. L., & Rostami‐Hodjegan, A. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.53 · Cited by 368 · see citing works

Prediction of Intestinal First-Pass Drug Metabolism

Yang, J., Jamei, M., Yeo, K., Tucker, G., & Rostami-Hodjegan, A. (2007) · Current Drug Metabolism · doi:10.2174/138920007782109733 · Cited by 366 · see citing works

Is the Role of the Small Intestine in First-Pass Metabolism Overemphasized?

Lin, J. H., Chiba, M., & Baillie, T. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01402-9 · Cited by 354 · see citing works

A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352 · see citing works

A potentially hazardous interaction between erythromycin and midazolam

Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J., & Neuvonen, P. J. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.25 · Cited by 351 · see citing works

Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

Varma, M. V. S., Obach, R. S., Rotter, C. J., Miller, H., Chang, G., Steyn, S. J., El‐Kattan, A. F., & Troutman, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901371v · Cited by 332 · see citing works

Changes in liver volume from birth to adulthood: A meta-analysis

Johnson, T. N., Tucker, G. T., Tanner, M. S., & Rostami‐Hodjegan, A. (2005) · Liver Transplantation · doi:10.1002/lt.20519 · Cited by 323 · see citing works

First-pass metabolism of midazolam by the human intestine*

Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90162-9 · Cited by 323 · see citing works

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

Gertz, M., Harrison, A., Houston, J., & Galetin, A. (2010) · Drug Metabolism And Disposition · doi:10.1124/dmd.110.032649 · Cited by 317 · see citing works

Intestinal permeability and its relevance for absorption and elimination

Lennernäs, H. (2007) · Xenobiotica · doi:10.1080/00498250701704819 · Cited by 304 · see citing works

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test

Watkins, P. B., Wrighton, S. A., Barnett, J. L., Lown, K. S., Kunze, K. L., Thummel, K. E., & Kolars, J. C. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/n8xg-qs69 · Cited by 304 · see citing works

Estimation of the increase in solubility of drugs as a function of bile salt concentration

Mithani, S. D., Bakatselou, V., TenHoor, C. N., & Dressman, J. B. (1996) · Pharmaceutical Research · doi:10.1023/a:1016062224568 · Cited by 303 · see citing works

Solubility of sparingly-soluble ionizable drugs

Avdeef, A. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.008 · Cited by 300 · see citing works

The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids

Persson, E. M., Gustafsson, A.-S., Carlsson, A. S., Nilsson, R. G., Knutson, L., Forsell, P., Hanisch, G., Lennernäs, H., & Abrahamsson, B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8192-x · Cited by 267 · see citing works

IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5

Patki, K. C., Moltke, L. L., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.938 · Cited by 264 · see citing works

Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M. F., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 256 · see citing works

Why Are Some Properties More Difficult To Predict than Others? A Study of QSPR Models of Solubility, Melting Point, and Log P

Hughes, L. D., Palmer, D. S., Nigsch, F., & Mitchell, J. B. O. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci700307p · Cited by 218 · see citing works

Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance

Brown, H. S., Griffin, M., & Houston, J. B. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011569 · Cited by 212 · see citing works

The Drug Transporter−Metabolism Alliance: Uncovering and Defining the Interplay

Benet, L. Z. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900253n · Cited by 206 · see citing works

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Darwich, A. S., Neuhoff, S., Jamei, M., & Rostami‐Hodjegan, A. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328913 · Cited by 183 · see citing works

The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.

Holtbecker, N., Fromm, M. F., Kroemer, H. K., Ohnhaus, E. E., & Heidemann, H. T. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08415-6 · Cited by 178 · see citing works

Dissolution Modeling: Factors Affecting the Dissolution Rates of Polydisperse Powders

Lu, A. T. K., Frisella, M. E., & Johnson, K. C. (1993) · Pharmaceutical Research · doi:10.1023/a:1018917729477 · Cited by 166 · see citing works

Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice

Hukkinen, S. K., Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90188-4 · Cited by 139 · see citing works

Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling

Barter, Z., Chowdry, J., Harlow, J., Snawder, J. E., Lipscomb, J. C., & Rostami-Hodjegan, A. (2008) · Drug Metabolism And Disposition · doi:10.1124/dmd.108.021311 · Cited by 139 · see citing works

A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice

van Waterschoot, R. A. B., & Schinkel, A. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002584 · Cited by 137 · see citing works

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

Gertz, M., Houston, J. B., & Galetin, A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039248 · Cited by 135 · see citing works

Factors affecting the absolute bioavailability of nifedipine.

Rashid, T. J., Martin, U., Clarke, H., Waller, D., Renwick, A., & George, C. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04534.x · Cited by 133 · see citing works

Applications of Physiologically Based Absorption Models in Drug Discovery and Development

Parrott, N. J., & Lavé, T. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000155 · Cited by 123 · see citing works

Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human

Chiou, W. L., & Buehler, P. W. (2002) · Pharmaceutical Research · doi:10.1023/a:1016169202830 · Cited by 122 · see citing works

Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

Galetin, A., Gertz, M., & Houston, J. B. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.909 · Cited by 122 · see citing works

An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development

Reigner, B. G., Williams, P. E. O., Patel, I. H., Steimer, J., Peck, C. C., & van Brummelen, P. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733020-00005 · Cited by 121 · see citing works

Simulating Fasted Human Intestinal Fluids: Understanding the Roles of Lecithin and Bile Acids

Söderlind, E., Karlsson, Ε., Carlsson, A., Kong, R., Lenz, A., Lindborg, S., & Sheng, J. J. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100144v · Cited by 119 · see citing works

In vitro–in vivoextrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions and correct concentrations

Pelkonen, O., & Turpeinen, M. (2007) · Xenobiotica · doi:10.1080/00498250701620726 · Cited by 118 · see citing works

Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids

Clarysse, S., Brouwers, J., Tack, J. F., Annaert, P., & Augustijns, P. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.04.016 · Cited by 115 · see citing works

Development of a 7-Day, 96-Well Caco-2 Permeability Assay with High-Throughput Direct UV Compound Analysis

Alsenz, J., & Haenel, E. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000008043.71001.43 · Cited by 110 · see citing works

Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling

Jones, H. M., Gardner, I. B., Collard, W. T., Stanley, P. J., Oxley, P., Hosea, N. A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539680-000000000-00000 · Cited by 110 · see citing works

An Evaluation of the Utility of Physiologically Based Models of Pharmacokinetics in Early Drug Discovery

Parrott, N., Paquereau, N., Coassolo, P., & Lavé, T. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20419 · Cited by 107 · see citing works

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

Lown, K. S., Kolars, J. C., Thummel, K. E., Barnett, J. L., Kunze, K. L., Wrighton, S. A., & Watkins, P. B. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08440-5 · Cited by 103 · see citing works

Theoretical Dissolution Model of Poly-Disperse Drug Particles in Biorelevant Media

Okazaki, A., Mano, T., & Sugano, K. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21070 · Cited by 92 · see citing works

Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique

von Richter, O., Greiner, B., Fromm, M. F., FRASER, R., Omari, T. I., Barclay, M. L., Dent, J., Somogyi, A. A., & Eichelbaum, M. F. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117937 · Cited by 91 · see citing works

A New Physiologically Based, Segregated-Flow Model to Explain Route-Dependent Intestinal Metabolism

Cong, D. H. T. N. Q., Doherty, M., & Pang, K. S. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15132-x · Cited by 90 · see citing works

Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms

Tubić-Grozdanis, M., Hilfinger, J. M., Amidon, G. L., Kim, J. S., Kijek, P., Staubach, P., & Langguth, P. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9519-6 · Cited by 84 · see citing works

From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example

Sinha, V. K., Snoeys, J., Osselaer, N. V., Peer, A. V., Mackie, C. E., & Heald, D. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1782 · Cited by 83 · see citing works

Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine

Damkier, P., Hansen, L. L., & Brøsen, K. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00099.x · Cited by 79 · see citing works

Effect of OROS ® controlled‐release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride

Sathyan, G., Chancellor, M. B., & Gupta, S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01463.x · Cited by 78 · see citing works

P-glycoprotein deficient mouse in situ blood–brain barrier permeability and its prediction using an in combo PAMPA model

Dagenais, C., Avdeef, A., Tsinman, O., Dudley, A., & Béliveau, R. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.06.009 · Cited by 75 · see citing works

Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers

Ho, P.-C., Ghose, K., Saville, D. J., & Wanwimolruk, S. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000189 · Cited by 73 · see citing works

Grapefruit juice increases oral nimodipine bioavailability.

Fuhr, U., Maier-Brüggemann, A., Blume, H. H., Mueck, W., Unger, S., Kuhlmann, J., Huschka, C., Zaigler, M., Rietbrock, S., & Staib, A. H. (1998) · PubMed · Cited by 72 · see citing works

Segmental Intestinal Transporters and Metabolic Enzymes on Intestinal Drug Absorption

Tam, D., Tirona, R. G., & Pang, K. S. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.373 · Cited by 70 · see citing works

Grapefruit Juice-Drug Interaction Studies as a Method to Assess the Extent of Intestinal Availability: Utility and Limitations

Gertz, M., Davis, J. D., Harrison, A. C., Houston, J. B., & Galetin, A. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049276 · Cited by 68 · see citing works

Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates

Fenneteau, F., Poulin, P., & Nekka, F. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21802 · Cited by 66 · see citing works

Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine

Poirier, A., Funk, C., Scherrmann, J., & Lavé, T. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002495 · Cited by 61 · see citing works

Predicting Drug – Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein

Tachibana, T., Kato, M., Takano, J., & Sugiyama, Y. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328922 · Cited by 59 · see citing works

Physiologically based approaches towards the prediction of pharmacokinetics:in vitro–in vivoextrapolation

Buck, S. S. D., & Mackie, C. E. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.6.865 · Cited by 58 · see citing works

Prediction of the Intestinal First-pass Metabolism of CYP3A and UGT Substrates in Humans from in vitro Data

Nishimuta, H., Sato, K., Yabuki, M., & Komuro, S. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-034 · Cited by 57 · see citing works

The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans

Takahashi, M., Washio, T., Suzuki, N., Igeta, K., & Yamashita, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21708 · Cited by 57 · see citing works

Influence of grapefruit juice on cisapride pharmacokinetics

Gross, A. S., Goh, Y. I., Addison, R. S., & Shenfield, G. M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70133-5 · Cited by 57 · see citing works

Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co‐medication interactions

Bohets, H., Lavrijsen, K., Hendrickx, J., Houdt, J. V., Genechten, V. V., Verboven, P., Meuldermans, W., & Heykants, J. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703246 · Cited by 55 · see citing works

Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model

Cubitt, H. E., Yeo, K. R., Howgate, E. M., Rostami‐Hodjegan, A., & Barter, Z. E. (2011) · Xenobiotica · doi:10.3109/00498254.2011.560294 · Cited by 55 · see citing works

Prediction of Drug Tissue to Plasma Concentration Ratios Using a Measured Volume of Distribution in Combination With Lipophilicity

Jansson‐Löfmark, R., Bredberg, U., & Ashton, M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21130 · Cited by 53 · see citing works

In SilicoModeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate

Abuasal, B., Bolger, M. B., Walker, D. K., & Kaddoumi, A. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200275j · Cited by 49 · see citing works

In Silico Prediction of Drug Permeability Across Buccal Mucosa

Kokate, A., Li, X., Williams, P. J., Singh, P., & Jasti, B. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9831-4 · Cited by 48 · see citing works

Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects.

Sigusch, H. H., Henschel, L., Kraul, H., Merkel, U., & Hoffmann, A. (1994) · PubMed · Cited by 40 · see citing works

Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A

Zhao, P., Lee, C. A., & Kunze, K. L. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013847 · Cited by 36 · see citing works

Kinetics and Mechanism of the Equilibrium Reaction of Triazolam in Aqueous Solution

Konishi, M., Hirai, K., & Mori, Y. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600711206 · Cited by 35 · see citing works

Prediction of the Intestinal First-Pass Metabolism of CYP3A Substrates in Humans Using Cynomolgus Monkeys

Nishimuta, H., Sato, K., Mizuki, Y., Yabuki, M., & Komuro, S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034561 · Cited by 30 · see citing works

Thermodynamic enthalpy–entropy compensation effects observed in the complexation of basic drug substrates with β-cyclodextrin

Omari, M. M. A., Zughul, M. B., Davies, J. E. D., & Badwan, A. A. (2007) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-006-9254-3 · Cited by 23 · see citing works

Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes.

Liu, X., Ren, Y., Qian, Z.-Y., & Wang, G. (2000) · PubMed · Cited by 19 · see citing works

Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil

Kharasch, E. D., Vangveravong, S., Buck, N. S., London, A. N., Kim, T., Blood, J., & Mach, R. H. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.313 · Cited by 16 · see citing works

Is the Metabolism of Alfentanil Subject to Debrisoquine Polymorphism? A Study Using Human Liver Microsomes

Lavrijsen, K., Houdt, J. V., Dyck, D. M. J. V., Hendrickx, J. J. J. M., Woestenborghs, R. J. H., Lauwers, W., Meuldermans, W., & Heykants, J. (1988) · Anesthesiology · doi:10.1097/00000542-198810000-00013 · Cited by 15 · see citing works

Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment

ISKANDER, M., LEUNG, L., Buley, T., Ayad, F., DIIULIO, J., Tan, Y. Y., & Coupar, I. M. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2005.07.017 · Cited by 15 · see citing works

Computer Models for Predicting Drug Absorption

Parrott, N. J., & Lavé, T. (2016) · CRC Press eBooks · doi:10.3109/9781420077346-16 · Cited by 5 · see citing works

PBPK models for the prediction of in vivo performance of oral dosage forms

Kostewicz, E. S., Aarons, L. J., Bergstrand, M., Bolger, M. B., Galetin, A., Hatley, O. J. D., Jamei, M., Lloyd, R. S., Pepin, X. J. H., Rostami‐Hodjegan, A., et al. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.008 · Cited by 316 · see citing works

In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim

Sjögren, E., Westergren, J., Grant, I., Hanisch, G., Lindfors, L., Lennernäs, H., Abrahamsson, B., & Tannergren, C. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.05.019 · Cited by 168 · see citing works

Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network

Vinarov, Z., Abrahamsson, B., Artursson, P., Batchelor, H. K., Berben, P., Bernkop‐Schnürch, A., Butler, J., Ceulemans, J., Davies, N. M., Dupont, D., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.001 · Cited by 155 · see citing works

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142 · see citing works

Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology

Gordon, S. (2015) · ALTEX · doi:10.14573/altex.1510051 · Cited by 142 · see citing works

Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine

Hartmanshenn, C., Scherholz, M. L., & Androulakis, I. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9492-y · Cited by 136 · see citing works

Alternatives of Animal Models for Biomedical Research: a Comprehensive Review of Modern Approaches

Vashishat, A., Patel, P., Gupta, G. D., & Kurmi, B. D. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10701-x · Cited by 108 · see citing works

Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

Peters, S. A., Jones, C. R., Ungell, A.-L. B., & Hatley, O. J. D. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0351-6 · Cited by 105 · see citing works

Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib

Parrott, N. J., Yu, L. J., Takano, R., Nakamura, M., & Morcos, P. N. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9957-3 · Cited by 77 · see citing works

Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration

Baneyx, G., Parrott, N. J., Meille, C., Iliadis, A., & Lavé, T. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.002 · Cited by 77 · see citing works

Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery

Gobeau, N., Stringer, R., De Buck, S., Tuntland, T., & Faller, B. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1951-z · Cited by 67 · see citing works

In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B

Qazzaz, M. E., Raja, V. J., Lim, K., Kam, T., Lee, J. B., Gershkovich, P., & Bradshaw, T. D. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.013 · Cited by 61 · see citing works

Applications of a 7-day Caco-2 cell model in drug discovery and development

Peng, Y. H., Yadava, P., Heikkinen, A. T., Parrott, N. J., & Railkar, A. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.008 · Cited by 57 · see citing works

Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine

Heikkinen, A. T., Friedlein, A., Matondo, M., Hatley, O. J. D., Petsalo, A., Juvonen, R. O., Galetin, A., Rostami‐Hodjegan, A., Aebersold, R. H., Lamerz, J., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1446-8 · Cited by 56 · see citing works

Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib

Parrott, N. J., Stillhart, C., Lindenberg, M., Wagner, B., Kowalski, K., Guerini, E., Djebli, N., & Meneses‐Lorente, G. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00463-y · Cited by 54 · see citing works

The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery

Moss, D. M., Curley, P., Kinvig, H., Hoskins, C., & Owen, A. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1399794 · Cited by 54 · see citing works

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans

Takahashi, R., Choo, E. F., Ma, S., Wong, S., Halladay, J. S., Deng, Y., Rooney, I. A., Gates, M. R., Hop, C. E. C. A., Khojasteh, S. C., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066282 · Cited by 46 · see citing works

An evaluation of the latestin vitrotools for drug metabolism studies

Costa, A., Sarmento, B. F. C. C., & Seabra, V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.857402 · Cited by 42 · see citing works

Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model

Olivares‐Morales, A., Kamiyama, Y., Darwich, A. S., Aarons, L. J., & Rostami‐Hodjegan, A. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.10.018 · Cited by 40 · see citing works

Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models

Hansmann, S., Darwich, A., Margolskee, A., Aarons, L., & Dressman, J. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12618 · Cited by 38 · see citing works

Rationale and strategies for formulation development of oral fixed dose combination drug products

Moon, C., & Oh, E. (2016) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-016-0286-4 · Cited by 38 · see citing works

A Mechanistic Physiologically Based Pharmacokinetic-Enzyme Turnover Model Involving both Intestine and Liver to Predict CYP3A Induction-Mediated Drug–Drug Interactions

Guo, H., Liu, C., Li, J., Zhang, M., Hu, M., Xu, P., Liu, L., & Liu, X. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23613 · Cited by 37 · see citing works

Prediction of Drug Disposition on the Basis of its Chemical Structure

Stepensky, D. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0042-0 · Cited by 33 · see citing works

The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development

Heikkinen, A. T., Lignet, F., Cutler, P., & Parrott, N. J. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400147 · Cited by 30 · see citing works

Investigating Oral Absorption of Carbamazepine in Pediatric Populations

Kohlmann, P., Stillhart, C., Kuentz, M., & Parrott, N. J. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0149-6 · Cited by 30 · see citing works

Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs—a fenofibrate case example

Berthelsen, R., Sjögren, E., Jacobsen, J. B., Kristensen, J., Holm, R., Abrahamsson, B., & Müllertz, A. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.06.060 · Cited by 28 · see citing works

An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: the role of PBPK modeling

Alqahtani, S., Bukhari, I. A., Albassam, A. A., & Alenazi, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1482277 · Cited by 28 · see citing works

Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover

Qian, C.-Q., Zhao, K., Chen, Y., Liu, L., & Liu, X. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.026 · Cited by 27 · see citing works

A New Physiologically Based Pharmacokinetic Model for the Prediction of Gastrointestinal Drug Absorption: Translocation Model

Ando, H., Hisaka, A., & Suzuki, H. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060038 · Cited by 24 · see citing works

Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin

Park, M., Shin, S., Byeon, J., Lee, G., Yu, B. Y., & Shin, Y. G. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.1.107 · Cited by 24 · see citing works

A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators

Yang, Y., Zhang, Z., Li, P., Kong, W., Liu, X., & Liu, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050698 · Cited by 23 · see citing works

PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates

Reddy, M. B., Bolger, M. B., Fraczkiewicz, G., Frari, L. D., Luo, L., Lukáčová, V., Mitra, A., Macwan, J. S., Mullin, J. M., Parrott, N. J., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091325 · Cited by 23 · see citing works

Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling

Riley, R. J., & Wilson, C. E. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1013095 · Cited by 23 · see citing works

Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine

Docci, L., Umehara, K., Krähenbühl, S., Fowler, S. M., & Parrott, N. J. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00513-5 · Cited by 23 · see citing works

In Vitro to in Vivo Extrapolation and Physiologically Based Modeling of Cytochrome P450 Mediated Metabolism in Beagle Dog Gut Wall and Liver

Heikkinen, A. T., Fowler, S., Gray, L., Li, J., Peng, Y., Yadava, P., Railkar, A., & Parrott, N. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300692k · Cited by 20 · see citing works

In Vitro and In Silico ADME Prediction

Effinger, A., O’Driscoll, C. M., McAllister, M. S., & Fotaki, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-99593-9_13 · Cited by 20 · see citing works

Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models

Yamada, M., Inoue, S., Sugiyama, D., Nishiya, Y., Ishizuka, T., Watanabe, A., Watanabe, K., Yamashita, S., & Watanabe, N. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089599 · Cited by 20 · see citing works

Perfluoropolyether-Based Gut-Liver-on-a-Chip for the Evaluation of First-Pass Metabolism and Oral Bioavailability of Drugs

Wang, M., Sasaki, Y., Sakagami, R., Minamikawa, T., Tsuda, M., Ueno, R., Deguchi, S., Negoro, R., So, K., Higuchi, Y., et al. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00605 · Cited by 19 · see citing works

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling

Fuhr, L. M., Marok, F. Z., Mees, M., Mahfoud, F., Selzer, D., & Lehr, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071474 · Cited by 19 · see citing works

Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 2. Rational Bioavailability Design by Global Sensitivity Analysis To Identify Properties Affecting Bioavailability

Daga, P. R., Bolger, M. B., Haworth, I. S., Clark, R. D., & Martin, É. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00973 · Cited by 19 · see citing works

Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin

Parrott, N. J., Hainzl, D., Alberati, D., Hofmann, C., Robson, R. A., Boutouyrie, B. X., & Martin‐Facklam, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0061-x · Cited by 17 · see citing works

Assessing the impact of child/adult differences in hepatic first-pass effect on the human kinetic adjustment factor for ingested toxicants

Valcke, M., & Krishnan, K. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.11.006 · Cited by 14 · see citing works

In‐depth analysis of patterns in selection of different physiologically‐based pharmacokinetic modeling tools: Part II — Assessment of model reusability and comparison between open and non‐open source‐code software

Aldibani, H. K. A., Rajput, A. J., & Rostami‐Hodjegan, A. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2360 · Cited by 13 · see citing works

Quantitative aspects of drug permeation across in vitro and in vivo barriers

Krämer, S. D. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.10.013 · Cited by 13 · see citing works

Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate

Moss, D. M., Domanico, P. L., Watkins, M., Park, S., Randolph, R., Wring, S., Rajoli, R. K. R., Hobson, J., Rannard, S. P., Siccardi, M., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00105-17 · Cited by 12 · see citing works

Parameterization of small intestinal water volume using PBPK modeling

Maharaj, A., Fotaki, N., & Edginton, A. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.10.016 · Cited by 10 · see citing works

Physiologically Based Oral Absorption Modelling to Study Gut-Level Drug Interactions

Chung, J., & Kesisoglou, F. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.08.015 · Cited by 10 · see citing works

Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy

Williamson, B., Colclough, N., Fretland, A. J., Jones, B., Jones, R. D. O., & McGinnity, D. F. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200312104837 · Cited by 10 · see citing works

A New Intestinal Model for Analysis of Drug Absorption and Interactions Considering Physiological Translocation of Contents

Asano, S., Yoshitomo, A., Hozuki, S., Sato, H., Kazuki, Y., & Hisaka, A. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000361 · Cited by 9 · see citing works

Comment on “In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically-Based Absorption Models”

Turner, D. B., Liu, B., Patel, N. K., Pathak, S. M., Polak, S., Jamei, M., Dressman, J., & Rostami‐Hodjegan, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00469 · Cited by 9 · see citing works

Combination of a biopharmaceutic classification system and physiologically based pharmacokinetic models to predict absorption properties of baicalein in vitro and in vivo

Li, X., Sun, J., Zhong, L., Li, Y., Er, A. N., Li, T., Yang, L., & Dong, L. (2021) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2021.07.006 · Cited by 8 · see citing works

Quantitatively Predicting Effects of Exercise on Pharmacokinetics of Drugs Using a Physiologically Based Pharmacokinetic Model

Guo, Z., Gao, J., Liu, L., & Liu, X. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.124.001809 · Cited by 7 · see citing works

Ex vivo gut-hepato-biliary organ perfusion model to characterize oral absorption, gut-wall metabolism, pre-systemic hepatic metabolism and biliary excretion; application to midazolam

Stevens, L. J., van de Steeg, E., Doppenberg, J. B., Alwayn, I. P. J., Knibbe, C. A. J., & Dubbeld, J. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106760 · Cited by 6 · see citing works

Determinants of Intestinal Availability for P-glycoprotein Substrate Drugs Estimated by Extensive Simulation With Mathematical Absorption Models

Ando, H., Hatakeyama, H., Sato, H., Hisaka, A., & Suzuki, H. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.065 · Cited by 6 · see citing works

Implementing Safe and Sustainable by Design (SSbD) into pharmaceutical innovation

Sorani, J., Hischier, R., & Nowack, B. (2026) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2025.147280 · Cited by 5 · see citing works

Physiologically based in vitro – in vivo correlation of modified release oral formulations with non-linear intestinal absorption: A case study using mirabegron

Takahashi, Y., & Kambayashi, A. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114479 · Cited by 5 · see citing works

Predictive Biopharmaceutics and Pharmacokinetics

Yang, Y., Zhao, Y., Duan, J. Z., Zhao, P., Zhao, L. Y., & Zhang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802447-8.00015-7 · Cited by 5 · see citing works

Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography–Mass Spectrometric Method

Park, Y., Park, M., Byeon, J., Shin, S., Lee, B. I., Choi, J., Kim, N., Park, S., Park, M.-J., Lim, J.-H., et al. (2020) · Molecules · doi:10.3390/molecules25092209 · Cited by 4 · see citing works

Physiologically Based Pharmacokinetic (PBPK) Modeling and Pharmacokinetic Pharmacodynamic (PKPD) Modelling

Varnekar, S., Sohal, M., Tikale, N., Ruchitha Reddy, S., Bose, A., Pawar, S., & Kurkute, P. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_14 · Cited by 3 · see citing works

In Vitro and In Silico ADME Prediction

Effinger, A., Driscoll, C. M. O., McAllister, M. S., & Fotaki, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-50419-8_15 · Cited by 2 · see citing works

The influence of individual gastrointestinal physiology parameters on prediction of regional drug absorption

Jadhav, H., Augustijns, P., & Tannergren, C. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125943 · Cited by 2 · see citing works

Integrating In Vitro BE Checker with In Silico Physiologically Based Biopharmaceutics Modeling to Predict the Pharmacokinetic Profiles of Oral Drug Products

Niino, T., Masada, T., Takagi, T., Kataoka, M., Yoshida, H., Yamashita, S., & Kambayashi, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091222 · Cited by 2 · see citing works

Impact of Preclinical Verification in Physiologically Based Pharmacokinetic Modelling for First-in-Human Predictions: Application of a Published Model Building Strategy for Five Compounds

Jackson, C., Graves, R. H., Tran, T. T., & Miller, N. A. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01655-z · Cited by 2 · see citing works

PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?

Henriot, J., Dallmann, A., Dupuis, F., Perrier, J., & Frechen, S. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13249 · Cited by 2 · see citing works

In Vitro–In SilicoTools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds

Wagner, C., & Dressman, J. (2014) · Wiley eBooks · doi:10.1002/9781118783344.ch12 · Cited by 2 · see citing works

PBPK: IntegratingIn VitroandIn SilicoData in Physiologically Based Models

Jones, H. M., & Parrott, N. J. (2014) · Wiley eBooks · doi:10.1002/9781118783344.ch9 · Cited by 2 · see citing works

Neonatal PBPK model of midazolam and its metabolites for perinatal asphyxia and therapeutic hypothermia

Leys, K., Ozbey, A. C., Huang, M., Macente, J., Stroe, M., de Haan, T. R., Groenendaal, F., Jacqz-Aigrain, É., de Wildt, S. N., Allegaert, K., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70601 · Cited by 1 · see citing works

Diagnosing Biopharmaceutical Limitations

Jenkins, S. M., & Parker, D. D. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1399-2_4 · Cited by 1 · see citing works

Distribution: Principle, Methods, and Applications

Yanni, S. B. (2015) · Wiley eBooks · doi:10.1002/9781118838440.ch2

Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia

Lee, J. B., Zang, X., Zgair, A., Ooi, T. Q., Foley, D., Voronin, G. O., Kagan, L., Soukarieh, F., Gao, R., Shao, H., et al. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.05.006

Application of GastroPlusTM Modeling in Product Development: A Case Study for a Low-Dose Poorly Water-Soluble Compound

Li, J. (2022) · Global Journal of Pharmacy & Pharmaceutical Sciences · doi:10.19080/gjpps.10.2

Drug target mining and in silico screening of Tibetan plant metabolites for potential alleviation of Oroya fever, a neglected tropical disease

Basharat, Z., Raza, A., Ogaly, H. A., Al‐Zahrani, F. A. M., Saleem, U., Wei, C. R., Ahmed, I., Islam, M., Jadoon, S., & Kim, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-41159-1

Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach

McKnite, A. M., Hamadeh, A., Hunt, J. P., Green, D. J., Imburgia, C. E., Whelan, A., Hudson, R. E., Chevalier, A., Mathis, C. L., Yang, M. J., et al. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70240

Transitioning from Transcriptomics to Proteomics: Enhancing Mechanistic Accuracy in PBPK Modeling via Absolute Protein Abundances

Chen, N., Pugliano, A., Winter, M., Wu, K., & Annaert, P. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70316

Can PBPK Modeling Improve Compound Optimization and Medicinal Chemistry Decision-Making in Complex Chemical Space?

Esposito, S., & Cebrián, D. Á. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00425

Understanding the High Pharmacokinetic Variability of 5-Aminosalicylic Acid Drug Products Using Compartmental, Semi-mechanistic, and Mechanistic Pharmacokinetic Models

Kunjir, S. A., Dhyagala, S., Rohila, A., Kumar, A., Sirvi, P. K., & Malayandi, R. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03581-6

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

Gertz, M., Harrison, A., Houston, J., & Galetin, A. (2010) · Drug Metabolism And Disposition · doi:10.1124/dmd.110.032649 · Cited by 317 · see citing works

PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?

Henriot, J., Dallmann, A., Dupuis, F., Perrier, J., & Frechen, S. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13249 · Cited by 2 · see citing works

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

Gertz, M., Houston, J. B., & Galetin, A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039248 · Cited by 135 · see citing works

Quantitative Prediction of Intestinal Metabolism in Humans from a Simplified Intestinal Availability Model and Empirical Scaling Factor

Kadono, K., Akabane, T., Tabata, K., Gato, K., Terashita, S., & Teramura, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029322 · Cited by 52 · see citing works

Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development

Karlsson, F. H., Bouchène, S., Hilgendorf, C., Dolgos, H., & Peters, S. A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.051664 · Cited by 45 · see citing works